Tata Elxsi Launches ViTel™ Material Intelligence Solution for Med-Tech with Viridium AI

Tata Elxsi, in partnership with Viridium AI, has launched ViTel™, an AI-powered material intelligence solution for the Med-Tech industry. This innovative platform aims to help medical device manufacturers accelerate sourcing, engineering decisions, and compliance. ViTel™ leverages Viridium AI’s Knowledge Cloud and advanced AI models to transform scattered enterprise data into actionable insights, enhancing product development and regulatory readiness. The solution was formally introduced at DeviceTalks Boston 2026.

Tata Elxsi and Viridium AI Unveil ViTel™

Tata Elxsi, a global leader in design and technology services, has announced the launch of ViTel™, a groundbreaking Material Intelligence solution specifically designed for the Med-Tech industry. This new offering is a collaborative effort with Viridium AI, a prominent material intelligence platform company. ViTel™ is set to revolutionize how medical device manufacturers manage critical aspects of their operations, from sourcing to compliance, by harnessing the power of artificial intelligence.

Addressing Med-Tech Challenges with AI

The modern medical device landscape presents significant challenges for manufacturers. Material decisions now have a profound impact on profit margins, supply chain resilience, product development speed, and market access. Often, crucial product and material knowledge is fragmented across various systems like BOMs, supplier documents, ERP, and PLM, making it difficult to respond efficiently to new regulations or customer demands. ViTel™ directly addresses this by creating a unified, reusable Material Intelligence layer across the enterprise.

Key Features and Benefits of ViTel™

ViTel™ empowers teams to:

  • Identify material and supplier dependencies.
  • Assess country-of-origin and sourcing risks.
  • Evaluate alternative materials.
  • Understand where product or material risks impact cost, continuity, or market access.

The solution is powered by Viridium AI’s Knowledge Cloud, Chemical Digital Twin, and science-constrained AI models. It transforms disparate enterprise data into a dynamic product-material knowledge graph, connecting products, parts, materials, chemicals, suppliers, regulations, and evidence. This comprehensive approach ensures faster, more confident decision-making across sourcing, engineering, quality, and regulatory readiness.

Strategic Partnership and Vision

This collaboration combines Tata Elxsi’s three decades of experience in Med-Tech engineering and regulatory expertise with Viridium AI’s cutting-edge platform and technology innovation. Sreevatsa Sahasranaman, Senior Vice President and Head, Healthcare and Life Sciences at Tata Elxsi, stated, “ViTel™ brings Material Intelligence directly into the product and compliance workflows that matter most, helping our customers make faster, more confident decisions.” Niraj Deo, Chief Executive Officer of Viridium AI, added, “Partnering with Tata Elxsi through ViTel™ brings that capability directly into the hands of the teams who need it most.” The ViTel™ solution is being formally introduced at DeviceTalks Boston 2026.

About the Companies

Tata Elxsi is a global design and technology services company supporting customers across various industries, including healthcare and life sciences. Their Med-Tech services encompass product engineering, digital health, regulatory support, connected devices, and lifecycle transformation. The company’s Healthcare and Life Sciences practice is ISO 13485 certified.

Viridium AI is a Material Intelligence company focused on transforming fragmented product, material, chemical, and supplier data into actionable intelligence. Their platform aids in making informed decisions related to sourcing, engineering, quality, compliance, and risk management within complex manufacturing environments.

Source: BSE

Previous Article

Gujarat Fluorochemicals Audited Financial Results for FY 2025-26 Announced

Next Article

Avenir Investment RSC Ltd Substantial Acquisition Disclosure for Sammaan Capital Limited